European Companies Search Engine
EU funding (€6,667,801): Leveraging room temperature diamond quantum dynamics to enable safe, first-of-its-kind, multimodal cardiac imaging Hor1 Oct 2018 EU Research and Innovation programme "Horizon"
Overview
Text
Leveraging room temperature diamond quantum dynamics to enable safe, first-of-its-kind, multimodal cardiac imaging
Cardiovascular Diseases (CVDs) are the number 1 cause of death globally: more people die annually from CVDs than from any other cause. Despite emerging diagnostics tools and therapeutics, several areas of significant unmet need remain unaddressed among CVD patients. The ability to personalize cardiovascular medical care and improve outcomes, will require characterization of disease processes at a molecular level. The current state-of-the-art, e.g., Positron emission tomography (PET), does not provide detailed information about the chemical state of the tissue at a molecular level, therefore it remains difficult to accurately diagnose and confidently select appropriate therapy in many circumstances. The MetaboliQs project brings together two areas of European excellence - diamond-based quantum sensing and medical imaging. We will translate a newly developed hyperpolarization method for magnetic resonance imaging (MRI) based on the quantum dynamics of nitrogen-vacancy (NV) centers. This breakthrough quantum technology will enable previously unachievable, highly sensitive quantification of metabolic activity, paving the way for precision diagnostics and better personalized treatment of cardiovascular and other metabolic diseases. For realizing and eventually commercializing the technology, MetaboliQs brings together a world-class multidisciplinary consortium with end to end expertise - leading diamond quantum technology research institutes (Fraunhofer IAF - quantum-grade diamond growth and fabrication, HUJI - quantum sensing) and innovative companies (Element 6 - worldwide leader in synthetic diamonds, NVision - inventor of diamond-based polarization), as well as two expert users of hyperpolarized and cardiovascular MRI (TUM, ETH Zurich - first in continental Europe to conduct clinical trials of hyperpolarized MRI for cardiovascular disease) and the market leader in electron paramagnetic resonance and preclinical MRI (Bruker).
Funded Companies:
| Company name | Funding amount |
| BRUKER BIOSPIN GmbH | €228,800 |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | €936,813 |
| Element SIX (UK) Ltd. | €960,290 |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | €1,500,173 |
| KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM) | €1,220,401 |
| NVISION IMAGING TECHNOLOGIES GmbH | €1,430,938 |
| THE HEBREW UNIVERSITY OF JERUSALEM | €390,388 |
Source: https://cordis.europa.eu/project/id/820374
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "BRUKER BIOSPIN GmbH - EU funding (€6,667,801): Leveraging room temperature diamond quantum dynamics to enable safe, first-of-its-kind, multimodal cardiac imaging"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
